EGFR and metastatic neoplasm: In GEMSTONE-302 [NCT03789604],[31] eligible patients had histologically or cytologically confirmed stage IV squamous or non-squamous NSCLC without known EGFR sensitizing mutations, ALK, ROS1, or RET fusions, no previous systemic treatment for metastatic disease.